Search Results

Endotronix, Inc. today announced Premarket Approval (PMA) from the U.S Food and Drug Administration (FDA) of the company’s Cordella™ Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes.

Glucotrack, Inc. and The Technology Partnership, announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor, suggesting sensor longevity beyond three years, a year longer than the Company previously announced.

Frank Morese, CEO and CTO of Olea Sensor Networks, will speak at this year’s Telehealth Secrets Conference in Silicon Valley, October 2-4 addressing the benefits of machine learning diagnostic technologies for medical applications.

Endotronix, Inc. presented 6-month results from its PROACTIVE-HF pivotal trial. PROACTIVE-HF evaluated the company’s investigational Cordella Pulmonary Artery (PA) Sensor in New York Heart Association (NYHA) class III HF patients at risk of congestion.

Endotronix, Inc. today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor System to the U.S. Food and Drug Administration (FDA).

Inspira Technologies OXY BHN Ltd., a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, announced a significant advancement in its sensor technology by its team of experts.

Insulet Corporation announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes.